Top

Journal of Cardiovascular Translational Research

Published in:

01-02-2014

Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications

Authors: Rossella Marcucci, Gabriele Cioni, Betti Giusti, Cinzia Fatini, Lorenza Rossi, Maddalena Pazzi, Rosanna Abbate

Published in: Journal of Cardiovascular Translational Research | Issue 1/2014

Abstract

Cardiovascular diseases actually remain the leading cause of death and morbidity in Western countries, and it is the most common cause of death in American women accounting for about one third of all deaths. Women remain underrepresented in published trial literature relative to their disease prevalence. Strong evidence do exists demonstrating gender differences in efficacy (ischemic risk) and safety (bleeding risk) associated with antithrombotic treatment, mostly related to different values of body mass, and renal function in women than men. Several data show a higher platelet reactivity in females and a higher prevalence of high platelet reactivity on aspirin and clopidogrel therapy. In primary prevention, the use of aspirin is associated with a higher reduction of risk for ischemic stroke in females and for myocardial infarction in males. In the setting of ACS, female gender is associated with a significantly higher risk of bleeding. In summary, there are some gender-related aspects of guidance in the complex spectrum of the net clinical benefit related to antithrombotic treatment.

Department of Health and Human Services CDC. Leading causes of death in females. United States, 2004. www.cdc.gov/women/lcod.htm

Ford, E. S., & Capewell, S. (2007). Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. Journal of the American College of Cardiology, 50(22), 2128–2132.PubMedCrossRef

Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Wylie-Rosett, J., et al. (2011). Heart disease and stroke statistics—2011 update: a report from the American Heart Association. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation., 123(4), e18–e209.

Goldberg, R. J., Yarzebski, J., Lessard, D. D., & Gore, J. M. (1999). A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective. Journal of the American College of Cardiology, 33, 1533–1539.PubMedCrossRef

Lee, P. Y., Alexander, K. P., Hammill, B. B. G., Pasquali, S. K., & Peterson, E. D. (2001). Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA, 286, 708–713.CrossRef

Wessel, T. R., Arant, C. B., McGorray, S. P., Sharaf, B. L., Reis, S. E., Kerensky, R. A., NHLBI Women's Ischemia Syndrome Evaluation (WISE), et al. (2007). Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clinical Cardiology, 30(2), 69–74.PubMedCrossRef

BaireyMerz, C. N., Johnson, B. D., Sharaf, B. L., et al. (2003). Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE Study. Journal of the American College of Cardiology, 41, 413–419.CrossRef

Shaw, L. J., BaireyMerz, C. N., Azziz, R., et al. (2008). Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism, 93, 1276–1284.PubMedCrossRef

Miller, V. M., Garovic, V. D., Kantarci, K., Barnes, J. N., Jayachandran, M., Mielke, M. M., et al. (2013). Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. Biology of Sex Differences, 4(1), 6.PubMedCentralPubMedCrossRef

10.

Ross, L. A., & Polotsky, A. J. (2012). Metabolic correlates of menopause: an update. Current Opinion in Obstetrics and Gynecology, 24(6), 402–407.PubMedCrossRef

11.

Komukai, K., Mochizuki, S., & Yoshimura, M. (2010). Gender and the renin-angiotensin-aldosterone system. Fundamental and Clinical Pharmacology, 24(6), 687–698.PubMedCrossRef

12.

Vitale, C., Mendelsohn, M. E., & Rosano, G. M. (2009). Gender differences in the cardiovascular effect of sex hormones. Nature Reviews Cardiology, 6(8), 532–542.PubMedCrossRef

13.

Bucciarelli, P., & Mannucci, P. M. (2009). The hemostatic system through aging and menopause. Climacteric, 12(Suppl 1), 47–51.PubMedCrossRef

14.

Miller, V. M., Jayachandran, M., & Owen, W. G. (2007). Ageing, oestrogen, platelets and thrombotic risk. Clinical and Experimental Pharmacology and Physiology, 34(8), 814–821.PubMedCrossRef

15.

Miller, V. M., Jayachandran, M., Hashimoto, K., Heit, J. A., & Owen, W. G. (2008). Estrogen, inflammation, and platelet phenotype. Gender Medicine, 5(Suppl A), S91–S102.PubMedCrossRef

16.

Biino, G., Santimone, I., Minelli, C., Sorice, R., Frongia, B., Traglia, M., et al. (2013). Age- and sex-related variations in platelet count in Italy: a proposal of reference ranges based on 40987 subjects' data. PLoS One, 8(1), e54289.PubMedCentralPubMedCrossRef

17.

Segal, J. B., & Moliterno, A. R. (2006). Platelet counts differ by sex, ethnicity, and age in the United States. Annals of Epidemiology, 16(2), 123–130.PubMedCrossRef

18.

Bobbert, P., Stellbaum, C., Steffens, D., Schütte, C., Bobbert, T., Schultheiss, H. P., et al. (2012). Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy. Blood Coagulation and Fibrinolysis, 23(8), 723–728.PubMedCrossRef

19.

Singla, A., Bliden, K. P., Jeong, Y. H., Abadilla, K., Antonino, M. J., Muse, W. C., et al. (2013). Platelet reactivity and thrombogenicity in postmenopausal women. Menopause, 20(1), 57–63.PubMedCrossRef

20.

Breet, N. J., Sluman, M. A., van Berkel, M. A., van Werkum, J. W., Bouman, H. J., Harmsze, A. M., et al. (2011). Effect of gender difference on platelet reactivity. Netherlands Heart Journal, 19(11), 451–457.PubMedCentralPubMedCrossRef

21.

Leng, X. H., Hong, S. Y., Larrucea, S., Zhang, W., Li, T. T., Lopez, J. A., et al. (2004). Platelets of female mice are intrinsecally more sensitive to agonists than are platelets of males. Arteriosclòer Thromb Vasc Biol, 24, 376–381.CrossRef

22.

Johnson, M., Ramey, E., & Ramwell, P. W. (1975). Sex and age differences in human platelet aggregation. Nature, 253, 355–357.PubMedCrossRef

23.

Faraday, N., Goldschmidt-Clermont, P. J., & Bray, P. F. (1997). Sex differences in platelet GpIIb/IIIa activation. Thrombosis and Haemostasis, 77, 748–754.PubMed

24.

Kurrelmeyer, K., Becker, L., Becker, D., Yanek, L., Goldschmidt-Clermont, P., & Bray, P. F. (2003). Platelet hyperreactivity in women from families with premature atherosclerosis. Journal of the American Medical Womens Association, 58, 272–277.

25.

Eidelman, O., Jozwik, C., Huang, W., Srivastava, M., Rothwell, S. W., Jacobowitz, D. M., et al. (2010). Gender dependence for a subset of a low-abundance signaling proteome in human platelets. Human Genomics and Proteomics, 2010, 164906.PubMedCrossRef

26.

Hobson, A. R., Qureshi, Z., Banks, P., & Curzen, N. (2009). Gender and responses to aspirin and clopidogrel: insights using short thromboelastography. Cardiovascular Therapeutics, 27, 246–252.PubMedCrossRef

27.

Gurbel, P. A., Bliden, K. P., Cohen, E., Navickas, I. A., Singla, A., Antonino, M. J., et al. (2008). Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagulation and Fibrinolysis, 19, 268–275.PubMedCrossRef

28.

Becker, D. M., Segal, J., Vaidya, D., Yanek, L. R., Herrera-Galeano, J. E., Bray, P. F., et al. (2006). Sex differences in platelet reactivity and response to low dose aspirin therapy. JAMA, 295, 1420–1427.PubMedCrossRef

29.

Morikawa, M., Kojima, T., Inoue, M., & Tsuboi, M. (1986). Sex difference in the effect of aspirin on intracellular Ca²⁺ mobilization and thromboxane A2 production in rat platelets. Japanese Journal of Pharmacology, 40, 463–468.PubMedCrossRef

30.

Kelton, J. G., Hirsh, J., Carter, C. J., & Buchanan, M. R. (1978). Sex differences in the antithrombotic effects of aspirin. Blood, 52, 1073–1076.PubMed

31.

Gonzalez-Correa, J. A., Arrebola, M. M., Munz-Marin, J., Moreno, A., Guerreo, A., Arranz, I., et al. (2007). Gender differences in the effect of aspirin on retinal ischemia, prostanoid synthesis and nitric oxide production in experimental type 1-like diabetes. Vascular Pharmacology, 47, 83–89.PubMedCrossRef

32.

Miners, J. O., Grugurinovich, N., Whitehead, A. G., Robson, R. A., & Birkett, D. J. (1986). Influence of gender and oral contraceptives steroids on the metabolism of salicylic acid and acetylsalicylic acid. British Journal of Clinical Pharmacology, 22, 135–142.PubMedCentralPubMedCrossRef

33.

Buchanan, M. R., Rischke, J. A., Butt, R., Turpie, A. G., Hirsh, J., & Rosenfeld, J. (1983). The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thrombosis Research, 29(2), 125–139.PubMedCrossRef

34.

Maree, A. O., & Fitzgerald, D. J. (2004). Aspirin and coronary artery disease. Thrombosis and Haemostasis, 92, 1175–1181.PubMed

35.

Gum, P. A., Kottke-Marchant, K., Welsh, P. A., White, J., & Topol, E. J. (2003). A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology, 41, 961–965.PubMedCrossRef

36.

Patrono, C., Baigent, C., Hirsh, J., Roth, G., & American College of Chest Physicians. (2008). Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133(6 Suppl), 199S–233S.PubMedCrossRef

37.

Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis. New England Journal of Medicine, 353(22), 2373–2383.PubMedCrossRef

38.

Antithrombotic Trialists' Collaboration. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329), 71–86.CrossRef

39.

Lee, P. Y., Chen, W. H., Ng, W., Cheng, X., Yat-Yin Kwok, J., Tse, H. F., et al. (2005). Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. American Journal of Medicine, 118, 723–727.PubMedCrossRef

40.

Mehta, S. S., Silver, R. J., Aaronson, A., Abrahamson, M., & Goldfine, A. B. (2006). Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. American Journal of Cardiology, 97, 567–570.PubMedCrossRef

41.

Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Topol, E. J., CHARISMA Investigators, et al. (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine, 354(16), 1706–1717.PubMedCrossRef

42.

Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Topol, E. J., Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators, et al. (2008). Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation, 118(17), 1705–1712.PubMedCrossRef

43.

ISIS-2 Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2, 349–360.

44.

International Stroke Trial Collaborative Group. (1997). The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. Lancet, 349, 1569–1581.CrossRef

45.

CAST (Chinese Acute Stroke Trial) Collaborative Group. (1997). CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet, 349, 1641–1649.CrossRef

46.

Manson, J. E., Stampfer, M. J., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., et al. (1991). A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA, 266, 521–527.PubMedCrossRef

47.

Kjeldsen, S. E., Kolloch, R. E., Leonetti, G., Mallion, J. M., Zanchetti, A., Elmfeldt, D., et al. (2000). Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension, 18, 629–642.PubMedCrossRef

48.

De Gaetano, G., & Collaborative Group of the Primary Prevention Project. (2001). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet, 357, 89–95.PubMedCrossRef

49.

Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352, 1293–1304.PubMedCrossRef

50.

Berger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G., & Brown, D. L. (2006). Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA, 295, 306–313.PubMedCrossRef

51.

Jochmann, N., Stangl, K., Garbe, E., Baumann, G., & Stangl, V. (2005). Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. European Heart Journal, 26, 1585–1595.PubMedCrossRef

52.

Parodi, G., Marcucci, R., Valenti, R., Gori, A. M., Migliorini, A., Giusti, B., et al. (2011). High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA, 306, 1215–1223.PubMedCrossRef

53.

Sofi, F., Marcucci, R., Gori, A. M., Giusti, B., Abbate, R., & Gensini, G. F. (2010). Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost, 103, 841–848.PubMedCrossRef

54.

Marcucci, R., Gori, A. M., Paniccia, R., Giusti, B., Valente, S., Giglioli, C., et al. (2009). Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation, 119, 237–242.PubMedCrossRef

55.

Aradi, D., Komócsi, A., Vorobcsuk, A., & Serebruany, V. L. (2013). Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost, 109, 93–101.PubMedCrossRef

56.

Giusti, B., Gori, A. M., Marcucci, R., & Abbate, R. (2010). Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol, 6, 393–407.PubMedCrossRef

57.

Marcucci, R., Giusti, B., Paniccia, R., Gori, A. M., Saracini, C., Valente, S., et al. (2012). High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets, 23, 586–593.PubMedCrossRef

58.

Marcucci, R., Cenci, C., Cioni, G., Lombardi, A., Giusti, B., & Gensini, G. F. (2012). Antiplatelets in acute coronary syndrome: personal perspectives. Expert Rev Cardiovasc Ther, 10, 1487–1496.PubMedCrossRef

59.

Paniccia, R., Antonucci, E., Gori, A. M., Marcucci, R., Giglioli, C., Antoniucci, D., et al. (2007). Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. Journal of Thrombosis and Haemostasis, 5, 1839–1847.PubMedCrossRef

60.

Paniccia, R., Antonucci, E., Maggini, N., Miranda, M., Gori, A. M., Marcucci, R., et al. (2010). Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thrombosis and Haemostasis, 104, 287–292.PubMedCrossRef

61.

Patti, G., Nusca, A., Mangiacapra, F., Gatto, L., D'Ambrosio, A., & Di Sciascio, G. (2008). Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. Journal of the American College of Cardiology, 52, 1128–1133.PubMedCrossRef

62.

Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., et al. (2010). Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 121, 512–518.PubMedCrossRef

63.

Parodi, G., Bellandi, B., Venditti, F., Carrabba, N., Valenti, R., Migliorini, A., et al. (2012). Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. American Journal of Cardiology, 109(2), 214–218.PubMedCrossRef

64.

Berger, J. S., Bhatt, D. L., Cannon, C. P., Chen, Z., Jiang, L., Jones, J. B., et al. (2009). The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis. Journal of the American College of Cardiology, 54, 1935–1945.PubMedCrossRef

65.

Subherwal, S., Bach, R. G., Chen, A. Y., Gage, B. F., Rao, S. V., Newby, L. K., et al. (2009). Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation, 119, 1873–1882.PubMedCentralPubMedCrossRef

66.

Alexander, K. P., Chen, A. Y., Newby, L. K., Schwartz, J. B., Redberg, R. F., Hochman, J. S., CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators, et al. (2006). Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation, 114(13), 1380–1387.PubMedCrossRef

67.

Ahmed, B., Piper, W. D., Malenka, D., VerLee, P., Robb, J., Ryan, T., et al. (2009). Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention Registry. Circulation: Cardiovascular Interventions, 2(5), 423–429.

68.

Bowyer, L., Brown, M. A., & Jones, M. (2001). Vascular reactivity in men and women of reproductive age. American Journal of Obstetrics and Gynecology, 185(1), 88–96.PubMedCrossRef

69.

Angiolillo, D. J., Fernández-Ortiz, A., Bernardo, E., Barrera Ramírez, C., Sabaté, M., Fernandez, C., et al. (2004). Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? Journal of Invasive Cardiology, 16(4), 169–174.PubMed

70.

Boersma, E., Harrington, R. A., Moliterno, D. J., White, H., & Simoons, M. L. (2002). Platelet glycoprotein IIb=IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 359, 189–198.PubMedCrossRef

71.

Hara, K., Akiyama, Y., & Tajima, T. (1994). Sex differences in the anticoagulant effects of warfarin. Japanese Journal of Pharmacology, 66(3), 387–392.PubMedCrossRef

72.

Sullivan, R. M., Zhang, J., Zamba, G., Lip, G. Y., & Olshansky, B. (2012). Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). American Journal of Cardiology, 110(12), 1799–1802.PubMedCrossRef

73.

Fang, M. C., Singer, D. E., Chang, Y., Hylek, E. M., Henault, L. E., Jensvold, N. G., et al. (2005). Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation, 112(12), 1687–1691.PubMedCentralPubMedCrossRef

74.

Volgman, A. S., Manankil, M. F., Mookherjee, D., & Trohman, R. G. (2009). Women with atrial fibrillation: greater risk, less attention. Gender Medicine, 6(3), 419–432.PubMedCrossRef

75.

Poli, D., Antonucci, E., Grifoni, E., Abbate, R., Gensini, G. F., & Prisco, D. (2009). Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thrombosis and Haemostasis, 101(5), 938–942.PubMed

76.

Tsadok, M. A., Jackevicius, C. A., Essebag, V., Eisenberg, M. J., Rahme, E., Humphries, K. H., Pilote, L., et al. (2012). Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation, 126(23), 2680–2687.PubMedCrossRef

77.

Capodanno, D., & Angiolillo, D. J. (2010). Impact of race and gender on antithrombotic therapy. Thrombosis and Haemostasis, 104(3), 471–484.PubMedCrossRef

78.

Wang, T. Y., Angiolillo, D. J., Cushman, M., Sabatine, M. S., Bray, P. F., Smyth, S. S., Becker, R. C., et al. (2012). Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. Journal of the American College of Cardiology, 59(10), 891–900.PubMedCrossRef

Title: Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications
Authors: Rossella Marcucci
Gabriele Cioni
Betti Giusti
Cinzia Fatini
Lorenza Rossi
Maddalena Pazzi
Rosanna Abbate
Publication date: 01-02-2014
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 1/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9534-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes

Antiplatelet Therapy: Targeting the TxA2 Pathway

Monocyte–Platelets Aggregates as Cellular Biomarker of Endothelium-Dependent Coronary Vasomotor Dysfunction in Patients with Coronary Artery Disease

Cigarette Smoking and Antiplatelet Effects of Aspirin Monotherapy Versus Clopidogrel Monotherapy in Patients with Atherosclerotic Disease: Results of a Prospective Pharmacodynamic Study

Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease